BioSyent Inc. (RX.V)
| Previous close | 10.01 |
| Open | 9.93 |
| Bid | 9.50 x 0 |
| Ask | 10.50 x 0 |
| Day's range | 9.93 - 10.75 |
| 52-week range | 7.03 - 10.75 |
| Volume | |
| Avg. volume | 8,403 |
| Market cap | 121.635M |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | 18.10 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.18 (1.71%) |
| Ex-dividend date | 31 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
BioSyent In-Licenses Endocrinology Product for Canada
MISSISSAUGA, Ontario, June 12, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has entered into an agreement with a European partner for an exclusive license to register, market, sell and distribute a new endocrinology product in Canada. BioSyent Pharma and its European partner have agreed to seek Health Canada approval of the product by the end of 2024. “We are
- GlobeNewswire
BioSyent Releases Financial Results for Q1 2024
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights include: (CAD)Q1 2024% Change vs.Q1 2023Trailing Twelve Months(TTM) March 31, 2024% Change vs.TTMMarch 31, 2023Canadian Pharma Sales7,546,14418%30,689,34916%International Pharma Sales-0%1,047,747789%Total Company Sales7,733,63619%32,841,24420%EBITDA12,204,19345%8,614,03728%Net Income After Taxes (NIA
- GlobeNewswire
BioSyent Declares Second Quarter 2024 Dividend
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 2024, to shareholders of record at the close of business on May 31, 2024. This second quarter 2024 dividend compares with the first quarter 2024 dividend of $0.045 per common share. This dividend qualifies as an 'eligible dividend' f
